West Michigan Advisors LLC Makes New $606,000 Investment in Revolution Medicines, Inc. $RVMD

Key Points

• West Michigan Advisors opened a new position in Revolution Medicines, buying 7,604 shares valued at approximately $606,000 in Q4.
• The stock is overwhelmingly institutionally owned (94.34%); several large funds boosted stakes recently, including Farallon (now ~14.63M shares) and Nextech (now ~7.60M shares).
• Insiders have been net sellers—Mark A. Goldsmith sold 120,000 shares for about $18.01M and insiders sold ~184,592 shares (~$24.5M) last quarter—while analysts are mostly positive (average rating "Buy") with an average price target of $78.94 versus the recent stock price around $134.48.

West Michigan Advisors LLC bought a new position in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 7,604 shares of the company's stock, valued at approximately $606,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Farallon Capital Management LLC increased its holdings in Revolution Medicines by 2.1% in the 3rd quarter. Farallon Capital Management LLC now owns 14,625,692 shares of the company's stock worth $683,020,000 after purchasing an additional 300,000 shares in the last quarter. Baker BROS. Advisors LP increased its holdings in Revolution Medicines by 1.0% in the 3rd quarter. Baker BROS. Advisors LP now owns 9,455,357 shares of the company's stock worth $441,565,000 after purchasing an additional 90,385 shares in the last quarter. Nextech Invest Ltd. increased its stake in shares of Revolution Medicines by 20.7% in the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company's stock valued at $332,472,000 after buying an additional 1,304,347 shares during the period. Paradigm Biocapital Advisors LP increased its stake in shares of Revolution Medicines by 2.1% in the third quarter. Paradigm Biocapital Advisors LP now owns 6,223,291 shares of the company's stock valued at $290,628,000 after buying an additional 130,000 shares during the period. Finally, Bellevue Group AG raised its position in shares of Revolution Medicines by 21.7% during the third quarter. Bellevue Group AG now owns 5,573,838 shares of the company's stock worth $260,298,000 after acquiring an additional 994,538 shares during the last quarter. Institutional investors and hedge funds own 94.34% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on RVMD shares. Truist Financial raised Revolution Medicines to a "strong-buy" rating in a research note on Wednesday, March 25th. Jefferies Financial Group assumed coverage on shares of Revolution Medicines in a report on Monday, March 16th. They set a "buy" rating for the company. Benchmark restated an "overweight" rating on shares of Revolution Medicines in a research report on Tuesday, February 17th. UBS Group began coverage on shares of Revolution Medicines in a research report on Friday, February 27th. They issued a "buy" rating on the stock. Finally, Stifel Nicolaus restated a "buy" rating on shares of Revolution Medicines in a research report on Monday. Four research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $78.94.

Insider Activity at Revolution Medicines

In other Revolution Medicines news, insider Mark A. Goldsmith sold 120,000 shares of the stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $150.09, for a total value of $18,010,800.00. Following the transaction, the insider owned 276,698 shares in the company, valued at approximately $41,529,602.82. This represents a 30.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Margaret A. Horn sold 4,583 shares of the stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $455,916.84. Following the completion of the transaction, the chief operating officer owned 157,570 shares in the company, valued at approximately $15,675,063.60. The trade was a 2.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 184,592 shares of company stock worth $24,499,532 over the last quarter. 8.20% of the stock is owned by company insiders.

Revolution Medicines Stock Down 5.0%

Shares of Revolution Medicines stock opened at $134.48 on Friday. Revolution Medicines, Inc. has a one year low of $34.00 and a one year high of $155.70. The company has a debt-to-equity ratio of 0.16, a current ratio of 7.14 and a quick ratio of 7.14. The stock's 50-day moving average is $106.78 and its 200 day moving average is $88.60. The firm has a market cap of $26.65 billion, a price-to-earnings ratio of -22.75 and a beta of 1.01.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its earnings results on Wednesday, February 25th. The company reported ($1.86) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.30). During the same quarter in the prior year, the company posted ($1.12) earnings per share. Equities research analysts anticipate that Revolution Medicines, Inc. will post -7.57 EPS for the current year.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.